Moderna and Merck cut the risk of melanoma recurrence or death by 42%. Wall Street sold the stock.
Six melanoma specialists called it clinically meaningful. Dr. Michael Postow of Memorial Sloan Kettering said curing more early-stage patients would be extraordinary. The market heard this and sent Moderna down 18% by the close.
The vaccine, intismeran autogene, was tested on roughly 1,100 patients. It beat Keytruda alone. Doctors cheered. Traders wanted 49%.
That was the number from the smaller Phase 2 trial. The Phase 3 result missed it by seven points. Seven. Somewhere a man in a fleece vest is weeping over seven points, while a stranger with melanoma keeps living.
Moderna was up around 525% this year, even after Thursday's drop. That is not a stock price. That is a dare. You bought a company at 625% of its January value, and the cancer vaccine worked, but not hard enough for your taste.
Citi called the data a clinically meaningful advance. Then it kept its Sell rating and put the price target at $80. Even the bears congratulated the patients before asking for a refund.
Retail traders now face a hard question. Is a 42% reduction in recurrence or death a disappointment? Yes, if you paid for a miracle with margin. No, if you have skin.
The data leaked on social media first. Your edge was a screenshot. Everyone else had the same screenshot, plus a pulse.
The companies expect a 2027 launch. Patients will get a personalized vaccine built from their own tumor. You got a personalized loss built from your own greed.
Moderna invented a shot that teaches the body to hunt cancer. You couldn't teach yourself to sell before the news.
Photo by on Unsplash
Leave a Comment